Compositions comprising select meroterpenes and a linoleic component and the use thereof in regulating the endocannabinoid system (ECS), especially in controlling and/or reducing the levels of cortisol: thereby having a stress reducing or inhibition effect.

Compositions comprising select meroterpenes and a linoleic component and the use thereof in regulating the endocannabinoid system (ECS), especially in controlling and/or reducing the levels of cortisol: thereby having a stress reducing or inhibition effect.

The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.

The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.

A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long-chain omega-3 fatty acids as a means to further increase the nutritional value. The composition provides an effective increase in therapeutic and pharmacological properties in nutrition, and retards the rate of oxidation thereof.

A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long-chain omega-3 fatty acids as a means to further increase the nutritional value. The composition provides an effective increase in therapeutic and pharmacological properties in nutrition, and retards the rate of oxidation thereof.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.